Raymond James Maintains Strong Buy on Mirum Pharmaceuticals, Raises Price Target to $84
Portfolio Pulse from richadhand@benzinga.com
Raymond James analyst Steven Seedhouse maintains a Strong Buy on Mirum Pharmaceuticals (NASDAQ:MIRM) and raises the price target from $79 to $84.

August 21, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James maintains a Strong Buy on Mirum Pharmaceuticals and raises the price target from $79 to $84. This could potentially lead to an increase in the stock's price.
The news of Raymond James maintaining a Strong Buy on Mirum Pharmaceuticals and raising the price target indicates a positive outlook for the company. This could potentially lead to an increase in the stock's price as it suggests that the analyst believes the company is undervalued at its current price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100